Merck KGaA Signs a License Agreement with Y-Trap to Develop Antibody-Ligand Traps for Immuno-Oncology
Shots:
- Y-Trap to receive up front- pre/clinical development- regulatory & commercial milestones with royalties on sales. Merck KGaA & Y-Trap will explore pharmacology of Y-Trap multifunctional proteins while Merck will be responsible for development- manufacturing and commercialization activities
- The collaboration involves Y-Trap's platform of multifunctional antibody-ligand traps for immuno-oncology and Merck KGaA’s expertise in the research and development of bi-functional antibodies and proteins
- The Y-Trap platform exploits combinatorial protein engineering countering key determinants of immune dysfunction in the tumor microenvironment. The antibody-ligand traps have an ability to unleash potent antitumor immune responses offering an immunotherapeutic strategy for advanced/refractory cancer indications
Click here to read the full press release/ article
Ref: PRNewswire | Image: Merck KGaA
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com